Source:http://linkedlifedata.com/resource/pubmed/id/17033717
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2006-10-11
|
pubmed:abstractText |
Changes in drug sensitivity in Bcl-XL small interfering RNA (siRNA) transfected Hepg2 hepatocellular carcinoma cells were investigated in this study. Bcl-XL siRNA and negative siRNA expression vector were constructed and stably transfected into Hepg2 cells. Reverse transcription (RT)-PCR, western blot and immunofluorescence were used to detect the target gene expression at mRNA and protein levels. Drug sensitivity of the cells to 5-fluorouracil (5-FU) and hydroxycamptothecin (HCPT) were evaluated with MTT. The Bcl-XL mRNA and protein expression levels in Bcl-XL siRNA transfectants were reduced compared with negative siRNA transfectants or mock cells. MTT results showed that Bcl-XL siRNA transfected cells have a higher cell inhibition rate than negative vector transfected cells or untreated cells after treatment with 13, 130, 1300 and 13,000 mg/L of 5-FU. Bcl-XL siRNA transfected cells also showed increased drug-sensitivity compared with negative vector transfected cells or untreated cells after treatment with 0.18, 0.36, 0.72 and 1.44 mg/L HCPT. Flow cytometry (FCM) results demonstrated that the sub-G1 population increased in the Bcl-XL siRNA group, compared with the negative siRNA group and untreated control group, after the addition of 5-FU (1300 mg/L) and HCPT (0.72 mg/L). siRNA targeting Bcl-XL gene can specifically down-regulate Bcl-XL expression in Hepg2 cells, and can increase spontaneous cell apoptosis and sensitize cells to 5-FU or HCPT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/BCL2L1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-X Protein
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1672-9145
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
704-10
|
pubmed:meshHeading |
pubmed-meshheading:17033717-Antimetabolites, Antineoplastic,
pubmed-meshheading:17033717-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17033717-Camptothecin,
pubmed-meshheading:17033717-Carcinoma, Hepatocellular,
pubmed-meshheading:17033717-Cell Line, Tumor,
pubmed-meshheading:17033717-Fluorouracil,
pubmed-meshheading:17033717-Humans,
pubmed-meshheading:17033717-Liver Neoplasms,
pubmed-meshheading:17033717-RNA, Messenger,
pubmed-meshheading:17033717-RNA, Small Interfering,
pubmed-meshheading:17033717-bcl-X Protein
|
pubmed:year |
2006
|
pubmed:articleTitle |
Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.
|
pubmed:affiliation |
Institute of Pharmacy and Pharmacology, Nanhua University, Hengyang 421001, China. lei_xiaoyong@yahoo.com.cn
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|